Get Your Personalized Supplement StackSupplement Stack Quiz

Lactococcus Lactis Strain Plasma

Also known as: *Lactococcus lactis* subsp. *lactis* JCM 5805, LC-Plasma, *Lactococcus lactis* strain Plasma

Overview

Lactococcus lactis strain Plasma (LC-Plasma) is a lactic acid bacterium primarily found in fermented dairy products. This strain is notable for its immunomodulatory effects, demonstrating potential in treating viral infections such as HPV and COVID-19 by bolstering immune responses. LC-Plasma is characterized by its ability to activate plasmacytoid dendritic cells (pDCs), stimulating the release of type I and III interferons, which play critical roles in antiviral defense. Given its emerging status in research, LC-Plasma is currently the subject of ongoing clinical trials to assess its effectiveness and safety, although most evidence derives from small-scale studies and preclinical research, indicating a need for larger trials to confirm its efficacy.

Benefits

Evidence suggests that LC-Plasma may help clear high-risk anal HPV infections and reduce anal precancerous lesions by enhancing immune responses, which is particularly beneficial for men who have sex with men (MSM) populations. Additionally, it is hypothesized to provide relief from mild COVID-19 symptoms by engaging the immune system more effectively. Secondary benefits include the stabilization of the skin microbiome, potentially improving skin conditions by preventing overgrowth of *Propionibacterium acnes*. While concrete effect sizes remain poorly defined, the studies indicate promising outcomes. Nevertheless, additional large-scale, high-quality clinical trials are necessary to establish definitive benefits.

How it works

LC-Plasma primarily exerts its effects by activating plasmacytoid dendritic cells, which leads to the production of type I and III interferons. These interferons play a vital role in inhibiting viral replication and enhancing both innate and adaptive immune responses. The activation of Toll-like receptor 9 (TLR9) has been identified as a key mechanism in this process, illustrating LC-Plasma's profound interaction with the immune system.

Side effects

Overall, LC-Plasma is regarded as safe based on limited studies, but comprehensive safety data are lacking. Common, uncommon, and rare side effects have not been well-documented in the available research, thus raising questions about its broader safety profile. There are no significant drug interactions noted, and no specific contraindications are identified. Additionally, while there are no specific warnings for special populations such as pregnant women or immunocompromised individuals, caution is advised due to the current limited understanding of its safety.

Dosage

The optimal dosage for LC-Plasma has not been definitively established; however, preliminary studies suggest approximately 1 × 10^11 cells per day for skin health and around 200 mg per day to alleviate symptoms associated with mild COVID-19. No maximum safe thresholds have been defined, and there are no specific timing recommendations or notable absorption factors explained in the literature. LC-Plasma is generally administered in capsule form, but individual responses may vary, suggesting a need for further dosing studies.

FAQs

Is LC-Plasma available as a supplement?

Currently, LC-Plasma is not widely available as a supplement, and its usage should be guided by healthcare professionals.

Is LC-Plasma safe to use?

While generally considered safe, comprehensive safety data on LC-Plasma are limited, so caution is advised.

What is the recommended timing for taking LC-Plasma?

There are no specific timing or administration guidelines established for LC-Plasma.

What benefits can I expect from taking LC-Plasma?

Potential benefits include enhanced immune responses and symptom relief from viral infections, although it is not a cure.

Are there any common misconceptions about LC-Plasma?

Some may mistakenly believe LC-Plasma cures viral infections, but it primarily supports immune function.

Research Sources

https://journals.lww.com/md-cases/fulltext/2023/10000/efficacy_of_lactococcus_lactis_strain_plasma_on.5.aspx – This trial evaluates the efficacy of LC-Plasma on high-risk anal HPV infections, involving 150 MSM with a follow-up of 180 days. Preliminary data suggests it could significantly aid in clearing infections.
https://pubmed.ncbi.nlm.nih.gov/36104128/ – This exploration assesses the role of LC-Plasma in alleviating symptoms in mild COVID-19, with a sample size of 100 patients over 14 days, positing that the strain may boost immune responses.
https://www.mdpi.com/2076-2607/9/3/563 – This randomized controlled trial reviews LC-Plasma's impact on skin health, highlighting its ability to stabilize the microbiome and improve skin conditions based on findings from 70 healthy volunteers over an 8-week period.
https://pubmed.ncbi.nlm.nih.gov/33803200/ – This study discusses LC-Plasma's immunomodulatory potential, integrating data from clinical trials and evaluating its overall safety and efficacy for future applications.
https://www.medrxiv.org/content/10.1101/2022.02.13.22270913v1.full.pdf – Presenting an early assessment of LC-Plasma's effects on mild COVID-19 symptoms, this research outlines an exploratory approach emphasizing the need for thorough evidence-based conclusions.